Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun;178(12):2375-2392.
doi: 10.1111/bph.15432. Epub 2021 May 3.

Clinical applications for exosomes: Are we there yet?

Dany Perocheau  1 , Loukia Touramanidou  1 , Sonam Gurung  1 , Paul Gissen  1   2 , Julien Baruteau  1   2
Affiliations
Review

Clinical applications for exosomes: Are we there yet?

Dany Perocheau et al. Br J Pharmacol. 2021 Jun.

Abstract

Exosomes are a subset of extracellular vesicles essential for cell-cell communication in health and disease with the ability to transport nucleic acids, functional proteins and other metabolites. Their clinical use as diagnostic biomarkers and therapeutic carriers has become a major field of research over recent years, generating rapidly expanding scientific interest and financial investment. Their reduced immunogenicity compared to liposomes or viral vectors and their ability to cross major physiological barriers like the blood-brain barrier make them an appealing and innovative option as biomarkers and therapeutic agents. Here, we review the latest clinical developments of exosome biotechnology for diagnostic and therapeutic purposes, including the most recent COVID-19-related exosome-based clinical trials. We present current exosome engineering strategies for optimal clinical safety and efficacy, and assess the technology developed for good manufacturing practice compliant scaling up and storage approaches along with their limitations in pharmaceutical industry.

Keywords: cancer; exosome; immunomodulation; infectious diseases; inflammation; manufacturing; therapeutics.

PubMed Disclaimer

Conflict of interest statement

The authors are partially funded by a United Kingdom Research Council Innovate UK Biomedical Catalyst award (14720) awarded jointly with Evox Therapeutics.

Figures

FIGURE 1
FIGURE 1
From mode of actions to therapies. Exosomes are promising players where their polymorph uses (orange) can influence their purpose (green) in clinical settings
FIGURE 2
FIGURE 2
Engineering strategies to refine a specific function and/or tropism to exosomes. Depending on their parent cell line, exosomes can express intrinsic ligands or can be engineered to express specific targeting ligands, stimuli response peptide, fusion protein, immune‐evasive components, or viral glycoproteins. Their cargos can vary from small‐sized genetic material such as noncoding RNAs to components as large as AAV. Exosome engineering can enable specific targeting of the central nervous system, systemic organs, or tumours. AAV: adeno‐associated vector, HEK: human embryonic kidney, MSC: mesenchymal stem cells, PEG: polyethylene glycol, TRAIL: TNF‐related apoptosis‐inducing ligand
FIGURE 3
FIGURE 3
Exosomes manufacturing for clinical use: from the laboratory to the industry. Schematic highlighting current differences between academic and industrial scale up. Exosomes can be derived from a cell bank or from the patients themselves. Laboratory set up predominantly uses a cell flask platform while the scaling up process involves bioreactors. While bioreactors increase yields and purity, exosomes need to be adequately characterised. FACS: fluorescence‐activated cell sorting, LC/MS: liquid chromatography‐mass spectrometry, MSC: mesenchymal stem cells, ME: microenvironment, NTA: nanoparticle tracking analysis
See this image and copyright information in PMC

References

    1. Alexander, S. P. H., Cidlowski, J. A., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., Pawson, A. J., Sharman, J. L., Southan, C., Davies, J. A., & GTP collaborators . (2019). The Concise Guide to PHARMACOLOGY 2019/2020: Nuclear hormones receptors. British Journal of Pharmacology, 176, S229–S246. 10.1111/bph.14748 - DOI - PMC - PubMed
    1. Alvarez‐Erviti, L., Couch, Y., Richardson, J., Cooper, J. M., & Wood, M. J. (2011). Alpha‐synuclein release by neurons activates the inflammatory response in a microglial cell line. Neuroscience Research, 69(4), 337–342. - PubMed
    1. Alvarez‐Erviti, L., Seow, Y., Schapira, A. H., Gardiner, C., Sargent, I. L., Wood, M. J., & Cooper, J. (2011). Lysosomal dysfunction increases exosome‐mediated alpha‐synuclein release and transmission. Neurobiology of Disease, 42(3), 360–367. - PMC - PubMed
    1. Alvarez‐Erviti, L., Seow, Y., Yin, H., Betts, C., Lakhal, S., & Wood, M. J. (2011). Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nature Biotechnology, 29(4), 341–345. - PubMed
    1. Andaloussi, S. E., Mäger, I., Breakefield, X. O., & Wood, M. J. (2013). Extracellular vesicles: Biology and emerging therapeutic opportunities. Nature Reviews. Drug Discovery, 12(5), 347–357. - PubMed

Publication types